Raptor Pharmaceuticals Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.08%178.890.7%$1150.86m
LLYEli Lilly & Co. 1.17%374.681.1%$1117.28m
MRKMerck & Co., Inc. 0.22%110.040.7%$1021.82m
PFEPfizer Inc. -0.37%50.890.9%$965.33m
ABBVAbbVie, Inc. 1.24%163.641.9%$868.91m
BMYBristol-Myers Squibb Co. 0.27%81.101.1%$765.35m
AZNAstraZeneca Plc 0.19%68.471.0%$350.56m
HZNPHorizon Therapeutics Plc 3.94%104.855.4%$310.89m
IDXXIDEXX Laboratories, Inc. -0.88%435.303.9%$216.72m
CTLTCatalent, Inc. 0.13%52.301.9%$206.27m
GSKGSK Plc 0.89%35.340.3%$187.83m
NVSNovartis AG 0.15%89.950.2%$184.65m
ALNYAlnylam Pharmaceuticals, Inc. 6.43%234.408.0%$174.69m
NVONovo Nordisk A/S 0.62%126.910.1%$165.68m
SRPTSarepta Therapeutics, Inc. 2.66%126.2512.4%$128.59m

Company Profile

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.